Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases

Jung Min Kim; Jae Hee Cheon

doi:10.5217/ir.2019.00128

Articles

Page Path: HOME > Intest Res > Volume 18(3); 2020 > Article

Review Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases: Jung Min Kim¹, Jae Hee Cheon^1,2,3; Intestinal Research 2020;18(3):249-264.
DOI: https://doi.org/10.5217/ir.2019.00128
Published online: April 18, 2020

¹Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

²Avison Biomedical Research Center, Severance Hospital, Seoul, Korea

³Affiliate Faculty, Pohang University of Science and Technology (POSTECH), Pohang, Korea

Correspondence to Jae Hee Cheon, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: +82-2-2228-1990, Fax: +82-2-393-6884, E-mail: geniushee@yuhs.ac

• Received: October 11, 2019 • Revised: November 25, 2019 • Accepted: March 6, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

25,370 Views
518 Download
53 Web of Science
53 Crossref
51 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
WHY ARE EIMs IMPORTANT IN IBD?
PATHOGENESIS OF EIMs
CLINICAL ASPECTS OF EIMs
TREATMENT FOR EIMs INCLUDING BIOLOGICS
KEY RECOMMENDATIONS FOR IMPROVING THE DISEASE COURSE AND PRINCIPLES TO BE APPLIED TO TREATMENT
CONCLUSIONS
NOTES
REFERENCES

Abstract

A considerable number of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), which can present either before or after IBD diagnosis. Unraveling the pathogenic pathways of EIMs in IBD is challenging because of the lack of reliable criteria for diagnosis and difficulty in distinguishing EIMs from external pathologies caused by drugs or other etiologies. Optimizing treatment can also be difficult. Early diagnosis and management of EIM revolve around multidisciplinary teams, and they should have the resources necessary to make and implement appropriate decisions. In addition, specialists of the affected organs should be trained in IBD treatment. Furthermore, patient awareness regarding the extraintestinal symptoms of IBD is of paramount importance for improving patient understanding of disease and health outcomes. Herein, we review the pathogenesis and clinical perspectives of EIMs in IBD.
Keywords: Inflammatory bowel diseases; Neuromuscular manifestations; Skin manifestations; Eye manifestations

INTRODUCTION

Inflammatory bowel disease (IBD), including CD and UC, is a chronic, intestinal inflammatory disease that is often associated with the development of various extraintestinal symptoms. Extraintestinal symptoms can be divided into 2 groups: extraintestinal manifestations (EIMs) and extraintestinal complications. EIMs are defined in patients with IBD when an inflammatory pathology is located outside the intestine, the pathogenesis of which depends on the extension/translocation of immune pathways from the intestine, is an independent inflammatory event sustained by IBD, or shares a common environmental or genetic predisposition with IBD [1]. EIMs can be divided into 3 categories: EIMs directly related to bowel disease activity, including episcleritis, erythema nodosum (EN), oral aphthous ulcers, and pauciarthritis; those not related to bowel disease activity but simply reflecting the patient’s susceptibility to related autoimmune disorders, including ankylosing spondylitis (AS) and uveitis; and those with an unclear relationship to bowel disease activity, including pyoderma gangrenosum (PG) and primary sclerosing cholangitis (PSC). Extraintestinal complications are initiated by the disease itself and consequently include micronutrient deficiency, osteoporosis, peripheral neuropathy, nephrolithiasis, and IBD drug-related side effects [2]. EIMs or extraintestinal complications occur in various organs and significantly affect the quality of life of patients with IBD (Table 1). Physicians who treat IBD need to keep track of the progress and treatment of these EIMs or extraintestinal complications of the disease through multidisciplinary approaches. Herein, we will focus on and review the pathogenesis and clinical perspectives of EIMs in IBD.

WHY ARE EIMs IMPORTANT IN IBD?

The prevalence of EIMs is strongly influenced by the age at diagnosis and sex [3,4] and is reported to be 23.0% in CD and 24.4% in UC, according to data from the National Health Insurance System of Korea [3]. Up to 50% of patients with IBD experience at least one EIMs, which can develop even before the diagnosis of IBD [5]. However, these results of EIMs differ greatly among study methods and research designs.

Abdominal pain is a common symptom related to IBD, and pain is the principal symptom in IBD [6]. Pain is a longstanding problem and can also be seen in EIMs [7]. During disease flares, pain is present in 50%^–70% of patients with IBD, and the health-related quality of life (HRQOL) of these patients was reported to be significantly lower in patients suffering from pain than in those without pain [6,7].

As such, EIMs are a common problem and may significantly impact the quality of life of patients with IBD, requiring specific treatments depending on the affected organs. Therefore, successful management of EIMs is essential for improving the quality of life of patients with IBD.

PATHOGENESIS OF EIMs

The pathogenic mechanisms of EIMs have yet to be clearly defined. Defining the pathophysiology of an EIM requires significant research and consensus due to the lack of consistent criteria for diagnosing an EIM and difficulty of distinguishing an EIM from extraintestinal complications or a secondary EIM caused by drugs. EIMs are considered to be the result of an antigen-specific immune response from the intestine to an extraintestinal site or an independent inflammatory event that is initiated or persisting from covalent genetic or environmental risk factors in the host, or from IBD (Fig. 1).

1. Dysbiosis of Gut Microbiota and Disrupted Gut Barrier in Intestinal Sites

Short chain fatty acids (SCFAs) enhance intestinal health, creating conditions favorable for resistance to pathogenic bacteria and preventing colitis. SCFAs have been found at significantly lower levels in IBD patients with psoriatic arthritis (PsA) [8]. IBD patients with PsA had a relative decrease in the abundance of Coprococcus and Ruminococcus species. Ruminococcus is a mucin-degrading bacterium that is especially important for maintaining intestinal homeostasis through SCFA production. The receptor activator of nuclear factor kappa-β ligand (RANKL)/ osteoprotegerin (OPG) system may be a regulator of intestinal microbiomes, and imbalances through the breakage of RANKL in the gut lumen of patients with PsA can promote dissociation of inflammation to a distal site, such as a joint [8].

IBD patients with spondyloarthritis (SpA) have an increased abundance of the genus Dialister, which is positively correlated with disease activity [9]. In addition, microbial activation in CD with SpA are associated with interleukin-23 (IL-23) dependent inflammation [10]. CD-SpA-derived Escherichia coli induced T helper 17 (Th17) cells polarization and made exacerbation of colitis or inflammatory arthritis.

Gut dysbiosis in IBD patients with AS induces differentiation and activation of group 3 congenital lymphocytes (IL-C3s) [11]. IL-C3s are IL-23-responsive immune cells that play a pro-inflammatory role in mediating a protective response against extracellular bacterial infections. IL-C3s have been identified in the peripheral blood, synovial fluid, and bone marrow tissues of patients with AS, most of which express intestinal homing integrin α₄β₇. Mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) was highly represented in the bone marrow and AS patients’ intestinal high endothelial venules. In addition, MAdCAM-1 plays a central role in attracting IL-C3s at the inflammation site of active AS and recirculating IL-C3s between the gut and inflamed spines [12]. In patients with IBD, intestinal effector T cells target gut microbial antigens. Transporting these antigens to the liver through the portal circulation allows the recruitment of mucosal effector α₄β₇ positive T cells through α₄β₇ MAdCAM-1 interactions.

Patients with PSC showed gut microbial differentiations from those with UC without liver diseases [13]. In a Gnotobiotic mice model with PSC/UC, Klebsiella pneumoniae, Proteus mirabilis and Enterococcus gallinarum were identified from the mesenteric lymph nodes of PSC/UC Gnotobiotic mice [14]. Disrupted gut barrier by K. pneumonia is associated with bacterial translocation and Th17 priming to the liver. These bacteria can lead the progression of hepatobiliary tract disease through the Th17 response in the colon and liver.

Alterations in the composition and metabolic products of the microbiota can affect the production of innate immune cells in patients with IBD [15,16]. There were significant differences in the composition of microbiome between HLA-B27+ and HLA-B27– siblings as well as healthy controls, indicating that genetic background can affect the composition and abundance of microbiomes.

Faecalibacterium prausnitzii-specific cells (DP8α TREG clones), found only in the chemokine receptor 6 (CCR6)⁺ and in the C-X-C motif chemokine receptor 6 (CXCR6)⁺ fractions of CD4CD8α (DP8α) cells, were significantly decreased in the blood of patients with IBD [17]. These gut recirculating markers are expressed in the DP8 cells of the large intestine and remain expressed in F. prausnitzii^–reactive DP8α cells in the blood, allowing them to move to a specific intestinal position to perform their functions. These characteristics can be conveyed by the joint expression of CCR6 and CXCR6; the expression of CCR6 and CXCR6 also implies homing to other mucosal locations.

2. Immune Responses in Extraintestinal Sites

Abnormal lymphocyte homing in IBD can explain why EIMs are associated with site specific distributions [18]. The α₄β₇ integrin is a lymphocyte receptor for the MAdCAM-1. The interaction between α₄β₇ and MAdCAM-1 plays an important role in regulating lymphocyte homing to mucosal sites [19]. Expression of MAdCAM-1 is confined to the intestinal tissue, allowing gut tropic T cells expressing α₄β₇ integrin to selectively traffic with the intestinal mucosa. Additional tropism for the small bowel comes from C-C motif chemokine ligand 25 (CCL25) which attracts lymphocytes expressing the CCR9 receptor. T cell migration to the small bowel requires integrin α₄β₇ [19] and CCR9 [20]. Interestingly, homing to the colon requires α₄β₇ or α4β1 but not CCR9 [21].

Both chemokines and adhesion molecules can promote T cell trafficking to extraintestinal sites. The activation and expansion of effector memory T cells can lead to the induction of MAdCAM-1 and CCL25 expression in the liver, thereby promoting the recruitment of CCR9⁺α₄β₇⁺ mucosal T cells and development of inflammation [22]. Upregulation of inflammation-related adhesion molecules and chemokines also enables the capture of effector T cells, facilitating recruitment to sites other than extraintestinal sites. IL-6 produced during inflammation promotes the influx of naïve and memory T cells by increasing the expression of intercellular adhesion molecule-1 (ICAM-1) in high endothelial venules of the reactive lymph nodes [23]. ICAM-1 can also be upregulated with pre-inflammatory stimuli in response to TNF-α, IL-1β, and interferon-γ [24].

Neutrophils altered by inflammatory cytokines can enhance their response upon subsequent activation, referred to as “neutrophil priming [25].” Neutrophils in patients with gut inflammation are primed to secrete high levels of TNF-α and IL-1β after stimulation with lipid polysaccharides [26]. However, patients with CD have a defective neutrophil recruitment after the introduction of subcutaneous bacteria, which severely delays the subsequent clearance of these bacteria [27]. In addition to changes in circulating monocytes and macrophages in patients with IBD, reduced inflammatory cytokine production in response to bacterial stimuli has also been reported [27,28]. Neutrophil-platelet interactions play an important role in the degree of tissue neutrophil infiltration through neutrophil integrins (α₁Lβ₂ and α_Mβ₂) and P-selectin glycoprotein ligand 1; however, neutrophil priming and/or activation in the peripheral site are inhibited by sphingosine [29,30]. Ceramide synthase 2 (CerS2) and CerS6 mutually control the aspects of neutrophil recruitment to tissues, and chemotaxis is also regulated by sphingosine-1-phosphate through IL-8 production. In the gut of patients with SpA, IL-23 polarization does not appear to be accompanied by Th17 polarization. However, IL-23 can induce gut inflammation and may be associated with the expansion and activation of innate immune cells such as IL-C3, γδ T cells, and mucosal-associated invariant T cells [11,31,32]. Augmented expression of IL-23R in γ/δ T cells was also associated with enhanced IL-17 secretion. Stimulation of γ/δ T cells from SpA patients with IL-23 and/or anti-CD3/CD28 strongly induced polarization for IL-17 production.

3. Autoantibodies

On the endothelial side, pre-incubation of the synovial sections with monoclonal antibodies against ICAM-1 and vascular adhesion protein-1 (VAP-1) showed significant inhibition of the binding of small lymphocytes from the IBD gut to the joint vessels [33]. Small lamina propria lymphocytes isolated from the intestine of IBD patients adhered to the synovial vessels using VAP-1 and their endothelial ligands (CD18 & ICAM1, and α₄β₇/α4β1 integrins and vascular cell adhesion molecule 1 [VCAM-1]). VAP-1 also plays a pivotal role in the recruitment and transmigration of lymphocytes via the hepatic sinusoidal endothelium, the expression of which is upregulated by inflammation [34]. VCAM-1 selectively binds lymphocytes through integrin α4β1. It also mediates lymphocyte homing to extraintestinal sites such as the lung, skin, and central nervous systems with chronic inflammation. It is not usually expressed by the intestinal venules but can be upregulated in the blood vessels during inflammation [35]. CCR10 with integrin α4β1 and VCAM-1 also mediate the localization of integrin α₄β₇-negative plasmablasts to non-intestinal mucosal sites (salivary and lacrimal glands and respiratory and urogenital tracts) where CCL28 is also expressed. Among the effector and central memory T cells, CCR10 is limited to integrin α4β1⁺α4β1^– cutaneous lymphocyte antigen⁺ skin homing cells (which provide T cell attraction to the CCR10 ligand CCL27 expressed in keratinocytes). Inflammation or mechanical stress in the extraintestinal sites can lead to the recruitment of gut-producing effector T cells and further increase the inflammatory process [34,36].

In addition, molecular mimicry, peptide sequences between the gut bacteria and host major histocompatibility complex (MHC) molecules, and reactivation by cross-reactive components of microbiomes or host antigens have been reported [37,38].

Peptides expressing common epitopes shared by colons and extra-colonic organs, autoimmune responses to the isoform of tropomyosin (tropomyosin related peptide) expressed in the eyes, skin, joints, biliary epithelia, and intestines can help clarify the pathogenesis of EIMs [39,40]. Bacteria can translocate across the leaky epithelial barriers and cause adaptive immune responses that are indistinguishable from bacterial epitopes in joints or skin. There is still a lack of clear evidence on the role of circulating antibodies or immune complexes in the pathogenesis of EIMs.

In a mice model, retina-specific T cells causing human blindness due to uveitis received microbial-dependent activation signals, most likely cross-reactive bacterial antigens [41]. This result showed that the activation of autoreactive T cells via gut microbes may drive uveitis. In another mice model of autoimmune uveitis, enhanced leukocytes trafficking between the intestine and eyes were observed [42]. The antigen specificity of T cells responsible for EIMs in humans will require further confirmation.

4. Genetics of EIMs

Genetic risk loci for both IBD and EIMs overlap extensively. PSC genes and their linked IBD genes are involved in T cell apoptosis (UBASH3A, BCL2L11, FOXO1, and IRF8) and the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways signaling pathways (SOCS1, JAK2, STAT3, and TYK2). In case of AS, T cell apoptosis pathways interact with the IBD genes. The AS-related genes, TAPBPL and NPEPPS, function similarly to the AS covalent gene ERAP1 in patients with IBD, which is important for both the development of AS and IBD. ERAP1 variant K528R associated with CD has involved in aberrant peptide production resulting in suboptimal peptide MHC I complex [43]. The CD risk gene, NOD2/CARD15, which encodes a pattern recognition receptor, is also associated with sacroiliitis and uveitis [44,45]. STAT4 is also responsible for the expansion of Th17 cells activated by IL-23, which promotes chronic inflammation in innate and adaptive immunity and is considerably associated with the development of EIMs involving the joints and eyes in patients with IBD [46]. However, it is still unknown whether all relevant loci contribute specifically to the pathology of EIMs or whether there are genes that generally cause EIMs by not restricting the inflammatory response to specific body compartments. Therefore, further research is needed.

CLINICAL ASPECTS OF EIMs

This following section describes the paradigms and tools currently available in clinical studies of the musculoskeletal/joint, skin, eye, vessels, and hepatobiliary EIMs (Table 2).

1. Musculoskeletal/Joint Manifestations

Inflammatory arthrosis of IBD is the most common EIM, with a prevalence of 20%^–50% for axial inflammation and 5%^–20% for peripheral arthritis [47]. Peripheral arthritis in patients with IBD is mainly asymmetric, oligo-articular, and is predominantly found in CD. IBD-related joint symptoms can be subdivided into non-inflammatory and inflammatory joint pain. Arthralgia is a major medical problem in patients with IBD. Compared to patients with IBD without arthralgia, non-inflammatory joint pain was reported in 16% of patients with a significant worsening of their HRQOL determined using the 36-Item Short-Form Health Survey and the Inflammatory Bowel Disease Questionnaire [48]. The current gold standard tool for layering SpA is the Ankylosing Spondylitis Disease Activity Score, which can measure the disease activity that may be followed over time [49]. In general, the prognosis for peripheral arthritis is good. The prognosis for axial involvement is less favorable and is not related to the prognosis of IBD but to the progression of IBD.

2. Skin Manifestations

Diagnoses of skin manifestations are primarily based on clinical examinations, and skin biopsies can help in atypical cases. EN is associated with IBD activity, arthralgia, or fatigue. The prevalence of EN appears higher in patients with CD than in those with UC [50]. EN usually appears on the extensor surface of the lower extremities, mostly in the anterior tibial region [51], and is associated with IBD flares but not always with severity, is self-limited, and usually resolves itself without the formation of ulcers or scarring [52]. The appearance of nodules parallels intestinal activity, which rarely occurs before the onset of IBD or in the quiescent phase of IBD. IBD treatment leads to the resolution of cutaneous lesions. PG can occur anywhere in the body but occurs most commonly in the shin and adjacent to stomas. PG usually has a skin trauma known as “pathergy.” This trauma might even be minimal, such as a venipuncture. Controversy exists over whether PG coexists with disease activity. In this case, treatment can be concentrated on the underlying intestinal disease. Patients often show a rapid response, with a stiffening of the lesions within 24 hours of treatment.

Due to the absence of specific tests for diagnosing PG, physicians can determine whether clinical and histopathological images are consistent with PG, excluding other pustules or ulcerative dermatitis. A further development of assessment tools and standardized classifications are needed.

3. Eye Manifestations

The most common ocular EIMs are dry eye, blepharitis, episcleritis, or anterior uveitis. Some ocular manifestations in IBD can be secondary to treatment and/or effects of the IBD itself. Ophthalmic complications usually originate from inflammation, but some of these complications may reflect the overall disease activity [53]. Episcleritis can be unilateral or bilateral and is more common in women. It usually does not need specific treatments other than those for the original disease. Scleritis is chronic and is characterized by edema and cellular infiltration of the scleral tissues. Uveitis is not common but can have potentially more serious consequences. It occurs acutely or subacutely and is usually very painful. Anterior uveitis is also commonly referred to as iritis, which indicates pain and photophobia and can be associated with blurred vision or floaters. The slit-lamp test confirms the diagnosis of an ocular EIM. In case of vision impairment, the patient must be immediately referred to the ophthalmologist to avoid vision loss.

4. Vascular Manifestations

Cardiovascular manifestations in IBD mostly occur as an immune-related pathogenesis including pericarditis, myocarditis, venous and arterial thromboembolisms, arrhythmias and conduction disorders, infective endocarditis, and Takayasu’s arteritis. Pericarditis is the most frequent cardiovascular EIM in patients with IBD but has not been associated with IBD activity [54]. The clinical picture of myocarditis or pericarditis related to IBD is nonspecific. These patients may have symptoms of an acute coronary syndrome, heart failure, or arrhythmias and may also have cardiogenic shock or sudden death.

If this clinical picture occurs within the first 28 days after starting treatment with 5-aminosalicylic acid or its derivatives, drug toxicity is suspected [55]. Because 12-lead electrocardiograms and biomarkers of cardiac injury are also nonspecific, transthoracic echocardiography, coronary angiography, or cardiovascular magnetic resonance imaging may offer more precise information for all patients with clinical presentations suggesting myopericarditis [56]. Furthermore, endomyocardial biopsies can be considered a gold standard for the diagnosis of myocarditis [57].

In meta-analysis studies, the risk of arterial thromboembolic events or cardiovascular mortality in patients with IBD does not increase but is associated with an increase in the risk of cardiovascular morbidities from cerebrovascular accidents and ischemic heart disease, especially in women [58,59]. Lower rates of peripheral vascular disease in IBD do not appear to increase the risk of peripheral arterial thromboembolic diseases. However, hyperhomocysteinemia, a risk factor for arterial and venous thrombosis, is more common in patients with IBD than in the general population [60]. In addition, an increased risk of arterial thrombosis due to systemic inflammation and hypercoagulability involves premature atherosclerosis [61].

5. Hepatobiliary Manifestations

Approximately 20% to 30% of patients with IBD show abnormal hepatic biochemistries [62]. PSC is highly correlated with IBD, and about 50%^–80% of patients with PSC have an accompanying IBD [63]. Patients with IBD and PSC often have predominantly right-sided, high-frequency “backwash” ileitis, and rectal sparing [64]. Patients with UC, when diagnosed with PSC, are negatively associated with smoking and older ages [65]. Symptoms are intermittent and can be confusing due to the underlying IBD symptoms. In patients with IBD, PSC is usually asymptomatic, which requires an awareness of high clinical association. Although typically imaged using magnetic resonance cholangiography and confirmed using endoscopic retrograde cholangiopancreatography (ERCP), the Crohn’s and Colitis Organisation consensus group suggests that ERCP be performed only for intervention in stricture dilatation and/or if brush cytology specimen sampling is indicated [66].

Autoimmune hepatitis (AIH)/PSC overlapping syndrome is seen in UC patients than CD [67]. It is suspected that the characteristics of AIH and PSC in the same patient are present, and a definitive diagnosis of AIH is required according to the international AIH group criteria [68].

The prevalence of AIH in pediatric IBD patients is 1.6% [69]. AIH can be divided into 2 types. AIH type 1 is positive for antinuclear antibodies and/or smooth muscle antibodies, whereas AIH type 2 is liver/kidney microsomal type 1 and/or antiliver cytosol type 1 is positive. Even if antinuclear antibodies or smooth muscle antibodies is 1:20 or liver/kidney microsomal type 1 is 1:10 in children, it is associated with AIH in children [70].

Granulomatous hepatitis is a rare EIM of CD. The estimated prevalence is less than 1% of IBD. It may manifest fever, alkaline phosphatase, hepatosplenomegaly. Granulomatous hepatitis may be induced by mesalazine and sulfasalazine therapy [71].

In nonalcoholic fatty liver disease, IBD-specific risk factors include intraperitoneal abscesses, fistula disease, colitis severity, malnutrition, protein loss, and drug use.

Thiopurine and gallstones are the most common causes of acute pancreatitis in patients with IBD, and acute pancreatitis caused by thiopurine is generally not complicated and is selfl-imiting [72]. Most chronic pancreatitis cases in patients with IBD are idiopathic, and PSC is a less common cause. Exocrine pancreatic insufficiency appears to be the most common pancreatic symptom in IBD, but its clinical significance remains unknown.

TREATMENT FOR EIMs INCLUDING BIOLOGICS

Optimizing treatments is often challenging. There is lack of high-quality evidence to support the most commonly used treatment methods for EIMs and other treatment strategies that can complement them. Treatment of EIMs should be based on the severity of symptoms and their association with IBD activity. The primary goal is symptom control and preservation of mobility and function. In some cases, symptomatic treatment with physiotherapy may be sufficient (Table 3).

1. Joint Manifestations

Treatment of IBD-related arthropathy is based on SpA studies, predominantly AS. Patients with axial SpA should be co-managed by rheumatologists because of the potentially disruptive disease progress. Severity of type 1 arthritis usually runs parallel to IBD activity, and type 2 arthritis usually requires long-term treatment. Therefore, effective treatment of underlying gut inflammation is important for the treatment of peripheral arthritis.

Intensive physiotherapy may be helpful in AS, and NSAIDs should be used for a short time period due to their potential to activate underlying IBD [73]. Cyclooxygenase-2 inhibitors such as etoricoxib and celecoxib may be safer and have a lower risk of disease flare than conventional NSAIDs [74]. Sulfasalazine, methotrexate (MTX), and azathioprine are generally ineffective or only slightly effective in the treatment of AS. However, sulfasalazine is effective in treating patients with peripheral joint disease, especially those with a short disease duration [75]. Sulfasalazine is an optional treatment in patients with SpA and peripheral disease and may be effective for large joint arthropathy [76]. MTX and azathioprine are considered marginally effective in the treatment of peripheral arthropathy. For patients with intolerance, unresponsiveness, or poor response to NSAIDs, anti-TNF therapy is the preferred treatment because of the limited efficacy of MTX and thiopurine [77].

2. Skin Manifestations

Treatment of EN consists of treating the underlying IBD, and systemic steroids may be helpful. For patients with resistant or frequent relapses, immunomodulators and anti-TNF therapy can be considered alone or in combination [78].

PG treatment strategies are the same between IBD and non-IBD patients. Systemic corticosteroids are considered as the first-line treatment, and oral or intravenous tacrolimus with oral cyclosporines may be considered for refractory cases [79,80]. Anti-TNF therapy represents a new and effective treatment option for medically refractory PG cases.

3. Eye Manifestations

Due to the potential loss of vision, ophthalmologists must evaluate each suspected case to confirm the diagnosis and help guide the treatment. Dry eyes may be treated with topical lubricants. Episcleritis may be self-limiting and usually responds to underlying IBD treatment along with topical NSAIDs and glucocorticoids [81]. Uveitis requires urgent consultations with ophthalmologists and needs prompt treatment because of the risk of vision loss. Treatment usually consists of steroids. Other therapies (azathioprine, MTX, or anti-TNF therapy) have been discussed only for resistant cases [82].

4. Vascular Manifestations

Because thromboembolism occurs due to multifactorial causes and acquired risk factors, precautions (hydration, correction of vitamin deficiencies, and wearing gradual compression stockings) can help prevent venous thromboembolisms (VTEs). Prophylactic anticoagulation therapy is recommended for high-risk patients (hospitalized due to an active phase or surgery) with VTEs [83]. There is still no evidence for the prophylaxis of active disease in outpatients with IBD. However, because many VTEs occur in outpatients with IBD, guidelines are required for VTE prophylaxis when patients with IBD have acutely or chronically active diseases. Acute deep vein thromboses and pulmonary embolisms are treated using anticoagulants according to international guidelines. Low-molecular-weight heparin is commonly used, and low-dose unfractionated heparin or fondaparinux can be used as an alternative option. Long-term treatment includes oral anticoagulants such as vitamin K antagonists (acenocoumarol, warfarin, fluindione) or non-vitamin K antagonist oral anticoagulants, such as dabigatran, rivaroxaban, apixaban, or edoxaban.

5. Hepatobiliary Manifestations

Ursodeoxycholic acid improves abnormal liver function tests and is widely used in patients with PSC, but prognosis improvements are controversial. Other therapeutic agents (steroid, cyclosporine, tacrolimus, MTX, or anti-TNF therapy) still lack evidence for improvements in clinical endpoints [84]. ERCPs play a role in the management of biliary strictures and should be performed after antibiotic prophylaxis in patients with PSC. It can reduce the risk of cholangitis, bacteremia, and septicemia after ERCP [85]. Patients with PSC and end-stage liver disease should be evaluated to determine whether liver transplantations should be performed according to the standard guidelines. PSC has a significantly greater risk for the development of colorectal dysplasia and carcinoma in patients with UC [86]. Therefore, surveillance colonoscopies with target biopsies are recommended at the diagnosis and at every 1^–2 years thereafter [87].

Immunosuppressive therapy with prednisolone alone or in combination with azathioprine is the main therapeutic regimen of AIH and has been to show the prolongation of life expectancy [67]. In granulomatous hepatitis, corticosteroids and immunosuppressive drugs are used for treatment.

6. Biologics and Probiotics for EIMs

Biologics have been tested to prove their efficacy in the treatment of EIMs as well as IBD. Clinical benefits of infliximab or adalimumab may not be limited to gut treatment effects but may extend to improve EIMs [88]. Infliximab and adalimumab therapy also have potential beneficial effects on metabolic bone diseases, hematologic diseases, or vascular EIMs [88]. However, anti-TNF treatments can cause paradoxical cutaneous inflammations, which are considered a class drug effect, and are generally reversible upon drug transition or discontinuation. This paradoxical cutaneous inflammation manifests itself or appears in most cases as psoriasis, which accounts for why anti-TNF-α drug use is increasingly recognized as a cause of drug-induced skin lesions [89]. Paradoxical psoriasis skin lesions are characterized by selective overexpression of type I interferon, skin accumulation of plasmacytoid dendritic cells (pDCs), and reduced T cell counts [90]. Anti-TNF-α treatment prolongs the production of type 1 interferons by pDC by inhibiting pDC maturation. Type I interferon overexpression results in a skin phenotype of paradoxical psoriasis, independent of T cells, unlike classical psoriasis. TNF-α inhibition may reduce the accumulation of Th1 and Th17 cells at the site of inflammation but may induce compensatory expansion at other locations, resulting in skin lesions [91].

The role of vedolizumab in EIM treatment has not been defined yet. Vedolizumab inhibits the binding of α₄β₇⁺ integrins to the intestinal mucosal cell adhesion molecule (MAdCAM-1) but not to VCAM-1 [92]. The binding mechanism seems to be selective for cutaneous intestinal lymphocyte migration. In contrast, lymphocyte migration by VCAM-1 is unaffected. Nevertheless, the overlapping binding behavior of α₄β₇ with MAdCAM-1 and VCAM-1 may be due to partly different affinities [92,93]. According to these results, vedolizumab has no direct therapeutic effect on cutaneous EIMs and can play a role in EIM management by treating disease activity in EIMs that parallels IBD [94]. In a systematic review, vedolizumab was suggested to reduce the incidence of new EIMs but also be effective in the treatment of preexisting EIMs (particularly PSC, rheumatic and cutaneous manifestations) [95].

Data on other biologicals are limited. Ustekinumab is a fully human IgG1 kappa monoclonal antibody that blocks the IL-12/23 p40 subunit. IL-12 and IL-23 are associated with adaptive immune responses, and blocking IL-12/IL-23 helps improve chronic inflammatory conditions. Ustekinumab has been reported for the management of cutaneous and joint EIMs (psoriasis, PsA) [96,97]. In addition, it is effective for the treatment of anti-TNF antibody-related paradoxical cutaneous inflammation [98]. However, paradoxical arthralgic or cutaneous manifestations have also been reported [99,100]. In addition, it did not reduce the occurrence of new EIMs [101]. Therefore, ustekinumab requires additional safety and efficacy evidence from randomized controlled trials and open-label, real-world cohorts. Ustekinumab will be an important treatment option in EIMs and IBD because it is superior to vedolizumab in terms of overall efficacy, rapid onset, and efficacy in small intestine disease.

Tofacitinib is a selective JAK inhibitor and the first oral medication approved for use in treating moderate-to-severe UC. Its efficacy of treating cutaneous EIMs has been reported. STAT3 was significantly upregulated in PG/EN compared to psoriasis and revealed potential benefits from JAK inhibition in these patients [94,102]. In a double-blind, head-to-head, non-inferiority, randomized controlled trial in patients with rheumatoid arthritis who had insufficient response to MTX treatment, combination therapy with tofacitinib and MTX showed similar efficacy to that with adalimumab and MTX, and tofacitinib monotherapy was shown to be inferior to either combination [103]. Because tofacitinib is expected to be free of anti-drug antibodies due to its low molecular weight, it results in a rapid therapeutic effect in patients with acute severe UC. Further studies on the efficacy and safety of the combination therapy with tofacitinib and other drugs are needed. In addition, there is a need to compare the efficacy and side-effects of upadacitinib and tofacitinib, which are selective JAK1 inhibitors.

Data on probiotics for EIMs are limited. Several studies suggested that the use of probiotics has a beneficial effect for cutaneous or arthralgic EIMs but requires further confirmation from randomized controlled trials or systematic reviews evaluating the effects of probiotics on EIMs [104,105].

KEY RECOMMENDATIONS FOR IMPROVING THE DISEASE COURSE AND PRINCIPLES TO BE APPLIED TO TREATMENT

Physicians should always consider EIMs in the management of patients with IBD. Early diagnosis and treatment can prevent permanent tissue destruction and the development of complications in patients with IBD with developing EIMs. Diagnostic delay is considered a risk factor for the development of EIM complications and abdominal surgery [106]. Uveitis can result in visual impairment if the diagnosis is delayed. Due to the diagnostic delay accompanying these inflammatory conditions, the need for proper approaches and tools that can quickly provide accurate and viable information is further emphasized. Sex, age, ethnicity, geography, socioeconomic status, duration, and extension of disease, disease activity, and a history of medications are associated with the diagnoses of EIMs. Genetic factors and dysbiosis of gut microbiomes also play an important role in identifying EIMs. Physicians should be careful because specific features of the clinical presentations may signal the possibility of future EIMs. Screening and surveillance of EIMs are difficult for physicians in only one specialty to include in their treatment protocols. Therefore, it is necessary to follow-up with multidisciplinary care. Educating patients on EIMs and their complications will improve the effectiveness of medications and follow-ups. However, research has shown that certain EIMs, such as VTEs, PSCs, and nephrolithiasis, may be less emphasized in patient education [107]. Patients’ perception of thromboembolisms or cardiovascular EIMs can have a significant impact on the associated morbidity and mortality. VTE has a higher incidence in patients with IBD than in the general population, and IBD disease activity is associated with an increased risk of VTE [108]. However, only 12% of patients were aware that the risk of VTE in the outpatient environment was high and less than half of the patients were convinced that they recognized the signs and symptoms of deep vein thromboses and pulmonary embolisms [107], indicating a need to reconsider the awareness of EIMs in patients with IBD.

The role of mobile applicable for the self-management of IBD by patients will continue to increase by providing a more efficient, effective, and good quality healthcare system at lower costs [109]. Daily monitoring of UC through TrueColours UC improved UC management while also reducing the burden placed on individual and healthcare services [110]. These applications can not only remotely monitor patients via electronic patient-reported outcome measures (PROs) or device-generated data (such as activity trackers) but also improves patient engagement [111]. The goal of recent IBD therapies is moving toward a therapeutic-targeted strategy using PROs, biomarkers of inflammation, and mucosal healing to optimize therapeutics and should also be used for the treatment of EIMs.

CONCLUSIONS

For EIMs of IBD, new mechanisms are being uncovered in a number of fields, including immunology, microbiology, and genetics, and can reveal a wide range of therapeutic targets. It is fundamentally important to ensure proper diagnosis and management of EIMs, which can often result in a much more debilitating and lower quality of life than actual IBD. Better patient images require new tools to monitor inflammation from various angles, and managements for complex and diverse EIMs should be discussed, treated, and tracked through multi-disciplinary care. In addition to establishing the required diagnosis and treatment process, patients should be encouraged to participate more actively in the various stages of medical care, measurements, implementations, and evaluations of the quality of their care.

NOTES

FINANCIAL SUPPORT

The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST

Cheon JH has been the Editor of MIntestinal Research since 2013. However, he was not involved in the peer reviewer selection, evaluation, or decision of this article. Except for that, no potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTION

Conceptualization, methodology, writing - original draft preparation: Kim JM. Writing - review and editing: Cheon JH. Supervision project administration: Cheon JH. Approval of final manuscript: all author.

Fig. 1.

Mechanisms of extraintestinal manifestations (EIMs). (a) Activation and expansion of effector memory T cells can lead to induction of mucosal vascular addressin cell adhesion molecule 1 and C-C motif chemokine ligand 25 (CCL25) expression in the liver. (b) Intercellular adhesion molecule-1, vascular adhesion protein-1, and vascular cell adhesion molecule 1 are associated with T cell trafficking. (c) Microbial antigens and materials translocate to extraintestinal sites and drive EIMs. (d) Circulating antibodies can provoke an autoimmune response and peptide(s) expressing common epitopes shared by colon and extra-colonic organs. (e) Neutrophil priming and alteration of circulating monocytes and macrophages can induce intestinal inflammation and are associated with innate immune responses. (f) Gut dysbiosis drives non-intestinal inflammation and increases mucosal permeability and lipopolysaccharides.

Table 1.

Extraintestinal Manifestations and Complications Associated with IBD

System	Extraintestinal manifestations (prevalence)			Complications of IBD
System	Directly related to bowel disease activity	Not related to bowel disease activity	Unclear relationship to bowel disease activity	IBD or its treatment
Joints/bone	Peripheral arthropathy (2%–20%)		-
	Type 1 peripheral arthritis	Type 2 peripheral arthritis		Metabolic bone disease
	Pauciarthritis	Ankylosing spondylitis (3%–20%)		Osteoporosis/osteopenia
		Axial arthritis (3%–25%)
Skin	Erythema nodosum (1%– 15%)	-	Pyoderma gangrenosum (1%–12%)	Drug-induced skin disease (anti-TNF-induced psoriasis, DIL-E)
				Drug hypersensitivity
				Drug-induced skin cancer
Eye	Episcleritis (<1%)	Uveitis (3%–11%)	-	Drug-induced cataracts
Cardiovascular	-	-	Infective endocarditis (0.2%–2.8%)	Drug-induced myocarditis
			Takayasu’s arteritis (<1%)	Drug-induced pericarditis
			Pericarditis (<1%)
Hepato-pancreato-biliary	-	-	Primary sclerosing cholangitis (0.2%–7.5%)	Drug-induced liver injury
			Nonalcoholic fatty liver disease (8%–59%)	Drug-induced pancreatitis
			Autoimmune hepatitis (0.6%–1.6%)	GB stones
			Granulomatous hepatitis (<1%)	Portal vein thrombosis
Coagulopathy	-	-	-	Venous thromboembolism

DIL-E, drug-induced lupus erythematosus; GB, gallbladder.

Table 2.

Diagnosis of Extraintestinal Manifestations

System	Extraintestinal manifestations	Diagnosis
Musculoskeletal/joint	Spondyloarthritis	Assessment of SpondyloArthritis International Society modified Berlin algorithm
			Without radiographic sacroiliitis
			HLA-B27 testing
			Evaluated for sacroiliitis by MRI
	Ankylosing spondylitis	Modified New York Classification criteria (≥1 radiological and ≥1 clinical)
		Clinical criteria
			Back pain and stiffness (≥3 months), improves with exercise, but is not relieved by rest
			Limitation of motion of the lumbar spine in both the sagittal and frontal planes
			Limitation of chest expansion relative to normal values correlated for age and sex
		Radiological criterion
			Image of sacroiliitis (grade ≥2 bilaterally or grade ≥3 unilaterally)
Skin	Erythema nodosum	Patient history and physical examination
	Erythema nodosum	Skin biopsy
	Pyoderma gangrenosum	Diagnostic criteria (≥ 1 major & ≥ 4 minor)
		Biopsy of ulcer edge demonstrating neutrophilic infiltrate
			Biopsy of ulcer edge
		Minor criteria
			Exclusion of infection
			Pathergy
			Personal history and history of papule, pustule, or vesicle
			Peripheral erythema, undermining border, and tenderness at site of ulceration
			Multiple ulcerations (≥ 1 anterior lower leg)
			Cribriform or “wrinkled paper” scar(s)
			Decrease in ulcer size within 1 month of initiating immunosuppressive medications
	Psoriasis	History and physical examination (Koebner phenomenon)
	Psoriasis	Skin biopsy (punch biopsy)
	Eczema	Diagnostic criteria
			Evidence of pruritic skin, including the report by a parent of a child rubbing or scratching
		In addition to itchy skin, 3 or more of the following are needed to make the diagnosis:
			History of skin, asthma or hay fever
			Dry skin within the past year
			Symptoms beginning in a child (<2 years of age)
			Visible dermatitis involving flexural surfaces
Eye	Episcleritis/scleritis	History and physical examination
	Episcleritis/scleritis	Slit-lamp biomicroscopy (ophthalmologist)
	Uveitis (anterior or posterior)	History and physical examination
	Uveitis (anterior or posterior)	Slit-lamp biomicroscopy (ophthalmologist)
Cardiovascular	Infective endocarditis	Fever±relevant cardiac risk factors or other predisposing conditions
		Modified Duke criteria
		ECG, CT, TTE, TEE, or chest X-ray
	Takayasu's arteritis	Clinical findings
	Takayasu's arteritis	MRA or CT angiography
	Pericarditis	ECG, echocardiography or chest X-ray
Hepato-pancreato-biliary	PSC	MRCP, ERCP, PTC
	NAFLD	History and rule out other disorders
		US, vibration controlled transient elastography
		CT, MRI or MRS
		Liver biopsy
Coagulopathy	Thromboembolism	Compression ultrasonography with Doppler
Coagulopathy	Thromboembolism	CT

HLA-B27, human leukocyte antigen-B27; ECG, electrocardiography; TTE, transthoracic echocardiography; TEE, transesophageal echocardiography; MRA, magnetic resonance angiography; PSC, primary sclerosing cholangitis; MRCP, magnetic resonance cholangio pancreatography; ERCP, endoscopic retrograde cholangiopancreatography; PTC, percutaneous transhepatic cholangiography; NAFLD, nonalcoholic fatty liver disease; US, ultrasound; MRS, magnetic resonance spectroscopy.

Table 3.

Treatments for Extraintestinal Manifestations

System	Extraintestinal manifestations	NSAIDs	Corticosteroids	5-ASA	MTX/AZA	Immunomodulators	Anti-TNFs
Musculoskeletal/joint	Spondyloarthritis	○	-	○	-	-	○
	Ankylosing spondylitis	○	-	△	△	-	○
	Peripheral arthritis	○	○	◎	○	-	○
Skin	Erythema nodosum	○	◎	-	-	-	○
Skin	Pyoderma gangrenosum	-	◎	-	-	○	○
Eye	Episcleritis/scleritis	○	○	-	△	-	△
Eye	Uveitis	-	○	-	△	△	△
Hepatobiliary	PSC		Ursodeoxycholic acid, ERCP and liver transplantation
	Autoimmune hepatitis		Prednisolone alone or in combination with azathioprine
	Granulomatous hepatitis	-	○	-	-	○	○
Coagulopathy	Deep vein thrombosis	Low-molecular-weight heparin, low-dose unfractionated heparin or fondaparinux
	Pulmonary embolism	Vitamin K antagonist (acenocoumarol, warfarin, fluindione)
	Thromboembolism	Non-vitamin K antagonist oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban)

5-ASA, 5-aminosalicylic acid; MTX, methotrexate; AZA, azathioprine; PSC, primary sclerosing cholangitis; ERCP, endoscopic retrograde cholangiopancreatography; ◎, recommended; ○, available; △, controversial.

REFERENCES

1. Hedin CRH, Vavricka SR, Stagg AJ, et al. The pathogenesis of extraintestinal manifestations: implications for IBD research, diagnosis, and therapy. J Crohns Colitis 2019;13:541–554.Article PubMed PDF
2. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1982–1992.Article PubMed PMC PDF
3. Yang BR, Choi NK, Kim MS, et al. Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients. PLoS One 2018;13:e0200363.Article PubMed PMC
4. Severs M, Spekhorst LM, Mangen MJ, et al. Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies. Inflamm Bowel Dis 2018;24:1298–1306.Article PubMed PDF
5. Vavricka SR, Rogler G, Gantenbein C, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the swiss inflammatory bowel disease cohort. Inflamm Bowel Dis 2015;21:1794–1800.Article PubMed
6. Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Crohn’s disease in the elderly: a comparison with young adults. J Clin Gastroenterol 1998;27:129–133.Article PubMed
7. Zeitz J, Ak M, Müller-Mottet S, et al. Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS One 2016;11:e0156666.Article PubMed PMC
8. Scher JU, Ubeda C, Artacho A, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol 2015;67:128–139.Article PubMed PMC
9. Tito RY, Cypers H, Joossens M, et al. Brief report: dialister as a microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol 2017;69:114–121.Article PubMed
10. Viladomiu M, Kivolowitz C, Abdulhamid A, et al. IgA-coated E. coli enriched in Crohn’s disease spondyloarthritis promote TH17-dependent inflammation. Sci Transl Med 2017;9:e. –aaf9655.Article
11. Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis 2015;74:1739–1747.Article PubMed
12. Cuthbert RJ, Fragkakis EM, Dunsmuir R, et al. Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol 2017;69:1816–1822.Article PubMed
13. Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut 2017;66:611–619.Article PubMed
14. Nakamoto N, Sasaki N, Aoki R, et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol 2019;4:492–503.Article PubMed PDF
15. Dodd D, Spitzer MH, Van Treuren W, et al. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. Nature 2017;551:648–652.Article PubMed PMC PDF
16. King SJ, McCole DF. Epithelial-microbial diplomacy: escalating border tensions drive inflammation in inflammatory bowel disease. Intest Res 2019;17:177–191.Article PubMed PMC PDF
17. Godefroy E, Alameddine J, Montassier E, et al. Expression of CCR6 and CXCR6 by gut-derived CD4⁺/CD8α⁺ T-regulatory cells, which are decreased in blood samples from patients with inflammatory bowel diseases. Gastroenterology 2018;155:1205–1217.Article PubMed
18. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006;6:244–251.Article PubMed PDF
19. Berlin C, Berg EL, Briskin MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993;74:185–195.Article PubMed
20. Svensson M, Marsal J, Ericsson A, et al. CCL25 mediates the localization of recently activated CD8alphabeta(⁺) lymphocytes to the small-intestinal mucosa. J Clin Invest 2002;110:1113–1121.Article PubMed PMC
21. Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol 2006;27:235–243.Article PubMed
22. Chapman RW. Aetiology and natural history of primary sclerosing cholangitis: a decade of progress? Gut 1991;32:14331435.Article
23. Chen Q, Fisher DT, Clancy KA, et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol 2006;7:1299–1308.Article PubMed PDF
24. Henninger DD, Panés J, Eppihimer M, et al. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 1997;158:1825–1832.Article PubMed PDF
25. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond) 1998;94:461–471.Article PubMed PDF
26. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998;42:470–476.Article PubMed PMC
27. Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J Exp Med 2009;206:1883–1897.Article PubMed PMC PDF
28. Sanders TJ, McCarthy NE, Giles EM, et al. Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn’s disease. Gastroenterology 2014;146:1278–1288.Article PubMed
29. Espaillat MP, Kew RR, Obeid LM. Sphingolipids in neutrophil function and inflammatory responses: mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis. Adv Biol Regul 2017;63:140–155.Article PubMed
30. Soehnlein O, Steffens S, Hidalgo A, Weber C. Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol 2017;17:248–261.Article PubMed PDF
31. Ciccia F, Accardo-Palumbo A, Alessandro R, et al. Interleukin-22 and interleukin-22-producing NKp44⁺ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum 2012;64:1869–1878.Article PubMed
32. Kenna TJ, Davidson SI, Duan R, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis. Arthritis Rheum 2012;64:1420–1429.Article PubMed
33. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol 2001;166:4650–4657.Article PubMed
34. Lalor PF, Edwards S, McNab G, Salmi M, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol 2002;169:983–992.Article PubMed
35. Soriano A, Salas A, Salas A, et al. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab Invest 2000;80:1541–1551.Article PubMed PDF
36. Jacques P, McGonagle D. The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it. Best Pract Res Clin Rheumatol 2014;28:703–710.Article PubMed
37. Scofield RH, Kurien B, Gross T, Warren WL, Harley JB. HLAB27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995;345:1542–1544.Article PubMed
38. Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, López de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002;277:37573–37581.Article PubMed
39. Oshitani N, Watanabe K, Nakamura S, Higuchi K, Arakawa T. Extraintestinal complications in patients with ulcerative colitis. Nihon Rinsho 2005;63:874–878.PubMed
40. Bhagat S, Das KM. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. Gastroenterology 1994;107:103–108.Article PubMed
41. Horai R, Zárate-Bladés CR, Dillenburg-Pilla P, et al. Microbiota-dependent activation of an autoreactive T cell receptor provokes autoimmunity in an immunologically privileged site. Immunity 2015;43:343–353.Article PubMed PMC
42. Nakamura YK, Janowitz C, Metea C, et al. Short chain fatty acids ameliorate immune-mediated uveitis partially by altering migration of lymphocytes from the intestine. Sci Rep 2017;7:11745.Article PubMed PMC PDF
43. Reeves E, James E. The role of polymorphic ERAP1 in autoinflammatory disease. Biosci Rep 2018;38–BSR20171503.Article PDF
44. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol 2002;14:337–337341.Article PubMed
45. Peeters H, Vander Cruyssen B, Laukens D, et al. Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann Rheum Dis 2004;63:1131–1134.Article PubMed PMC
46. Moon CM, Cheon JH, Kim SW, et al. Association of signal transducer and activator of transcription 4 genetic variants with extra-intestinal manifestations in inflammatory bowel disease. Life Sci 2010;86:661–667.Article PubMed
47. De Vos M, De Keyser F, Mielants H, Cuvelier C, Veys E. Review article: bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:397–404.Article PubMed
48. Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002;29:511–515.PubMed
49. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18111–1818.Article
50. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006;101:1012–1023.Article PubMed
51. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401–412.Article PubMed
52. Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005;81:580–585.Article PubMed PMC
53. Hopkins DJ, Horan E, Burton IL-, Clamp SE, de Dombal FT, Goligher JC. Ocular disorders in a series of 332 patients with Crohn’s disease. Br J Ophthalmol 1974;58:732–737.Article PubMed PMC
54. Kupferschmidt H, Langenegger T, Krähenbühl S. Pericarditis in chronic inflammatory bowel disease: underlying disease or side effects of therapy? Clinical problem solving. Schweiz Med Wochenschr 1996;126:2184–2190.PubMed
55. Brown G. 5-Aminosalicylic acid-associated myocarditis and pericarditis: a narrative review. Can J Hosp Pharm 2016;69:466–472.Article PubMed PMC
56. Kindermann I, Barth C, Mahfoud F, et al. Update on myocarditis. J Am Coll Cardiol 2012;59:779–792.Article PubMed
57. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:19141931.Article PDF
58. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 2014;8:469–479.Article PubMed PDF
59. Singh S, Singh H, Loftus EV Jr, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and metaanalysis. Clin Gastroenterol Hepatol 2014;12:382–393.Article PubMed
60. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther 2011;34:1173–1184.Article PubMed
61. Tan VP, Chung A, Yan BP, Gibson PR. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013;28:1095–1113.Article PubMed
62. Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007;102:344–350.Article PubMed
63. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991;11:31–39.Article PubMed PDF
64. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91–96.Article PubMed PMC
65. Park YE, Cheon JH, Park JJ, et al. Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study. Int J Colorectal Dis 2018;33:1497–1500.Article PubMed PDF
66. Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2016;10:239254.Article PDF
67. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology 2001;33:994–1002.Article PubMed
68. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544–553.Article PubMed
69. Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:63–68.Article PubMed PMC
70. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:21932213.Article
71. Braun M, Fraser GM, Kunin M, Salamon F, Tur-Kaspa R. Mesalamine-induced granulomatous hepatitis. Am J Gastroenterol 1999;94:1973–1974.Article PubMed
72. Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohns Colitis 2016;10:95–104.Article PubMed PDF
73. Klein A, Eliakim R. Non steroidal anti-inflammatory drugs and inflammatory bowel disease. Pharmaceuticals (Basel) 2010;3:1084–1092.Article PubMed PMC
74. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006;101:311–317.Article PubMed
75. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;(2): CD004800.Article PubMed
76. Dougados M, vam der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995;38:618–627.Article PubMed
77. Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new? Curr Rheumatol Rep 2012;14:422–427.Article PubMed PDF
78. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn’s disease. Rheumatol Int 2005;25:406–410.Article PubMed PDF
79. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:1273–1281.Article PubMed
80. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006;333:181–184.Article PubMed PMC
81. Mintz R, Feller ER, Bahr RL, Shah SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004;10:135–139.Article PubMed
82. Fries W, Giofré MR, Catanoso M, Lo Gullo R. Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol 2002;97:499–500.Article PubMed
83. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 2014;146:835–848.Article PubMed
84. Chandok N, Hirschfield GM. Management of primary sclerosing cholangitis: conventions and controversies. Can J Gastroenterol 2012;26:261–268.Article PubMed PMC PDF
85. Brand M, Bizos D, O’Farrell P Jr. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2010;(10): CD007345.Article PubMed PMC
86. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a metaanalysis. Gastrointest Endosc 2002;56:48–54.Article PubMed
87. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013;7:1–33.Article PubMed PDF
88. Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol 2017;15:25–36.Article PubMed
89. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223–231.PubMed
90. Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018;9:25.Article PubMed PMC PDF
91. Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease. Clin Rev Allergy Immunol 2017;53:413–427.Article PubMed PDF
92. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864–875.Article PubMed
93. Sody E, Körber A. Psoriasis induced by vedolizumab. Inflamm Bowel Dis 2017;23–E9-E11.Article PubMed
94. Vavricka SR, Galván JA, Dawson H, et al. Expression patterns of TNFα, MAdCAM1, and STAT3 in intestinal and skin manifestations of inflammatory bowel disease. J Crohns Colitis 2018;12:347–354.Article PubMed PDF
95. Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review. J Crohns Colitis 2019;13:1569–1577.Article PubMed PDF
96. Kavanaugh A, Puig L, Gottlieb AB, et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebocontrolled studies (PSUMMIT-1/PSUMMIT-2). Ann Rheum Dis 2016;75:1984–1988.Article PubMed
97. Greb JE, Gottlieb AB, Goldminz AM. High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum. Dermatol Ther 2016;29:482–483.Article PubMed
98. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibodyinduced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γexpressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014;63:567–577.Article PubMed
99. Čarija A, Ivić I, Marasović-Krstulović D, Puizina-Ivić N. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab. Rheumatology (Oxford) 2015;54:21142116.Article PDF
100. Gregoriou S, Kazakos C, Christofidou E, Kontochristopoulos G, Vakis G, Rigopoulos D. Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis. Eur J Dermatol 2011;21:104–105.Article PubMed
101. Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn’s disease: results of the ICC registry, a nationwide prospective observational cohort study. J Crohns Colitis 2020;14:33–45.Article PubMed PDF
102. Peyrin-Biroulet L, Danese S, Louis E, et al. DOP50 Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study. J Crohns Colitis 2019;13–Suppl 1:S057.Article
103. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, headto-head, randomised controlled trial. Lancet 2017;390:457468.Article
104. Satta R, Pes GM, Rocchi C, Pes MC, Dore MP. Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease? J Dermatolog Treat 2019;30:612–616.Article PubMed
105. Sanges M, Valente G, Rea M, et al. Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci 2009;13:233–234.PubMed
106. Manser CN, Borovicka J, Seibold F, et al. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J 2016;4:281–287.Article PubMed PMC
107. Huang V, Mishra R, Thanabalan R, Nguyen GC. Patient awareness of extraintestinal manifestations of inflammatory bowel disease. J Crohns Colitis 2013;7:e318–e324.Article PubMed PDF
108. Murthy SK, Nguyen GC. Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol 2011;106:713–718.Article PubMed PDF
109. Kelso M, Feagins LA. Can smartphones help deliver smarter care for patients with inflammatory bowel disease? Inflamm Bowel Dis 2018;24:1453–1459.Article PubMed PDF
110. Walsh A, Matini L, Hinds C, et al. Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intest Res 2019;17:365–374.Article PubMed PMC PDF
111. Atreja A, Otobo E, Ramireddy K, Deorocki A. Remote patient monitoring in IBD: current state and future directions. Curr Gastroenterol Rep 2018;20:6.Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Unraveling the causal association between inflammatory bowel diseases and uveitis through mendelian randomization analysis
Min Zhong, Hongjin An, Huatian Gan
Scientific Reports.2025;[Epub] CrossRef
Evaluating the anti-inflammatory and antioxidant efficacy of complementary and alternative medicines (CAM) used for management of inflammatory bowel disease: a comprehensive review
Sia Shin, Siqi Chen, Kangzhe Xie, Suehad Abou Duhun, Tamara Ortiz-Cerda
Redox Report.2025;[Epub] CrossRef
The causal impact of genetically predicted inflammatory bowel disease on extraintestinal manifestations: a mendelian randomization study
Xingcan Fan, Anqi He, Kaiyu Li, Maorun Zhang, Qi Zhang, Wanyi Xiao, Gang Liu
BMC Gastroenterology.2025;[Epub] CrossRef
Risk of malignancies and chemopreventive effect of statin, metformin, and aspirin in Korean patients with ulcerative colitis: a nationwide population-based study
Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
Intestinal Research.2025; 23(2): 129. CrossRef
Asociación entre colitis ulcerativa y embolia pulmonar: caso clínico
Edwar Jassir Rozo Ortíz, Javier Orlando Barón Barón, Ledmar Jovanny Vargas Rodriguez, Karina Briceño Díaz, Dania Fabiola Pérez Gómez
Revista colombiana de Gastroenterología.2025; 40(1): 104. CrossRef
Pyoderma gangrenosum, peripheral ulcerative keratitis, and oral ulcers in a patient with inflammatory bowel disease
Amanda T. Chung, Roy Luister C. Acos, John Paulo L. Recio, Giselle Marie S. Tioleco-Ver, Belen L. Dofitas
JAAD Case Reports.2025; 61: 78. CrossRef
Strain-specific responses to dextran sulfate sodium-induced ulcerative colitis in BALB/c and C57BL/6 mice: Comparative analysis of local versus extra-intestinal manifestations
Priyanka Tiwari, Gopabandhu Jena
Inflammation Research.2025;[Epub] CrossRef
Prevalence and risk factors of gallstone disease in Korean patients with ulcerative colitis
Kwangwoo Nam, Jae Yong Lee, Sang Hyoung Park, Ha Won Hwang, Ho-Su Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Jin Hwa Park, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Intestinal Research.2025; 23(4): 455. CrossRef
Inflammatory bowel diseases (IBDs): a cross-sectional analysis of the psychological and biological mechanisms underlying intestinal and extra-intestinal symptoms—GastroPsy study protocol
Alberto Caruso, Giovanni Latella, Dina Di Giacomo, Marco Cavicchioli, Federica Galli
BMJ Open.2025; 15(11): e103374. CrossRef
JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease
Fotios S. Fousekis, André Jefremow, Konstantinos H. Katsanos, Markus F. Neurath, Raja Atreya
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Long-term remission of severe refractory scleritis associated with ulcerative colitis after proctocolectomy: a case report and literature review
Kazuki Kurimura, Reiko Kunisaki, Katsuki Yaguchi, Shunsuke Shibui, Misa Onishi, Serina Haruyama, Yoshinori Nakamori, Kenichiro Toritani, Hideaki Kimura, Shin Maeda
Clinical Journal of Gastroenterology.2025;[Epub] CrossRef
Pomegranate seed oil mitigates liver and kidney damage in an experimental colitis model: Modulation of NF-κB activation and apoptosis
Açelya Gül Koyuncu, Alev Cumbul, Elvan Yilmaz Akyüz, Müge Kopuz Alvarez Noval
Prostaglandins & Other Lipid Mediators.2024; 171: 106804. CrossRef
Screening of silent inflammatory bowel disease in seronegative spondyloarthritis patients: Fecal calprotectin, ileo-colonoscopy and histopathology assessment
Shaimaa Badran, Andrew Saweres, Hadeel GamalEldeen, Mohamed B. Hashem, Dalia Abdel-kareem, Fatma H. Abdelraouf, Wafaa Gaber, Tamer Elbaz
The Egyptian Rheumatologist.2024; 46(1): 6. CrossRef
Leaky gut, circulating immune complexes, arthralgia, and arthritis in IBD: coincidence or inevitability?
Xi-ya Jin, Dan-dan Li, Wei Quan, Yang Chao, Bin Zhang
Frontiers in Immunology.2024;[Epub] CrossRef
Effect of ustekinumab on extraintestinal manifestations in patients with Crohn’s disease or ulcerative colitis
D. I. Abdulganieva, D. D. Mukhametova
Meditsinskiy sovet = Medical Council.2024; (8): 135. CrossRef
Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment
Ilaria Faggiani, Jacopo Fanizza, Ferdinando D’Amico, Mariangela Allocca, Alessandra Zilli, Tommaso Lorenzo Parigi, Alberto Barchi, Silvio Danese, Federica Furfaro
Biomedicines.2024; 12(8): 1839. CrossRef
Risk of Intestinal Complications, Extraintestinal Morbidity, and Mortality in Patients with Crohn’s Disease and Ocular Involvement
Amer F. Alsoudi, Karen M. Wai, Euna Koo, Ryan A. McConnell, Nathan H. Pham, Brian K. Do, Cassie A. Ludwig, Andrea L. Kossler, Prithvi Mruthyunjaya, Ehsan Rahimy
Ocular Immunology and Inflammation.2024; 32(10): 2486. CrossRef
The Leaky Gut and Human Diseases: “Can’t Fill the Cup if You Don’t Plug the Holes First”
Debora Compare, Costantino Sgamato, Alba Rocco, Pietro Coccoli, Carmen Ambrosio, Gerardo Nardone
Digestive Diseases.2024; 42(6): 548. CrossRef
Long‐term clinical outcomes of intestinal Behçet's disease: A 30‐year cohort study at a tertiary hospital in South Korea
Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon
Journal of Gastroenterology and Hepatology.2023; 38(3): 386. CrossRef
Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
Intestinal Research.2023; 21(2): 252. CrossRef
The Oral-Gut Axis: Periodontal Diseases and Gastrointestinal Disorders
Gretchen A Lam, Hala Albarrak, Cassidy J McColl, Alaina Pizarro, Harsha Sanaka, Adrian Gomez-Nguyen, Fabio Cominelli, Andre Paes Batista da Silva
Inflammatory Bowel Diseases.2023; 29(7): 1153. CrossRef
Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
So Jung Han, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(2): 111. CrossRef
Are the risks of colorectal cancer and biliary cancer really increased if patients with ulcerative colitis have primary sclerosing cholangitis?
Jung Wook Lee, Won Moon
Intestinal Research.2023; 21(2): 171. CrossRef
The Relationship Between Rosacea and Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Yu Kyung Jun, Da-Ae Yu, Yoo Min Han, Soo Ran Lee, Seong-Joon Koh, Hyunsun Park
Dermatology and Therapy.2023; 13(7): 1465. CrossRef
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
You Sun Kim, Edward H. Hurley, Yoojeong Park, Sungjin Ko
Intestinal Research.2023; 21(4): 420. CrossRef
Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
Jae-Young Lee, Hyun Woo Ma, Ji Hyung Kim, I Seul Park, Mijeong Son, Keun Ho Ryu, Jieun Shin, Seung Won Kim, Jae Hee Cheon
Gut and Liver.2023; 17(5): 766. CrossRef
Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease
Kwang Woo Kim, Hyoun Woo Kang
Intestinal Research.2023; 21(4): 413. CrossRef
Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef
Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
BMC Gastroenterology.2023;[Epub] CrossRef
Fermented rice bran supplementation attenuates chronic colitis-associated extraintestinal manifestations in female C57BL/6N mice
Jahidul Islam, Afifah Zahra Agista, Kouichi Watanabe, Tomonori Nochi, Hisashi Aso, Yusuke Ohsaki, Takuya Koseki, Michio Komai, Hitoshi Shirakawa
The Journal of Nutritional Biochemistry.2022; 99: 108855. CrossRef
Functional Gastrointestinal Disorders in Patients with Inflammatory Bowel Disease
Kyeong Ok Kim
The Korean Journal of Gastroenterology.2022; 79(1): 4. CrossRef
Is primary sclerosing cholangitis with inflammatory bowel disease different between patients in the East and West?
Yong Eun Park
Intestinal Research.2022; 20(2): 157. CrossRef
A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease
Kevin Cesa, Catherine Cunningham, Tyler Harris, Whitney Sunseri
Cureus.2022;[Epub] CrossRef
Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
Gut and Liver.2022; 16(4): 555. CrossRef
Medication Adherence in Korean Patients with Inflammatory Bowel Disease and Its Associated Factors
Kyunghwan Oh, Eun Ja Kwon, Jeong Hye Kim, Kyuwon Kim, Jae Yong Lee, Hee Seung Hong, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jeong Yun Park, Sang Hyoung Park
The Ewha Medical Journal.2022; 45(2): 35. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
Intestinal Research.2022; 20(4): 431. CrossRef
A Review of Ophthalmic Complications in Inflammatory Bowel Diseases
Wiktoria Pytrus, Katarzyna Akutko, Tomasz Pytrus, Anna Turno-Kręcicka
Journal of Clinical Medicine.2022; 11(24): 7457. CrossRef
Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study
Yu‐Ching Weng, Chao‐Kuei Juan, Hsiu J. Ho, Yi‐Ling Chang, Chun‐Ying Wu, Yi‐Ju Chen
The Journal of Dermatology.2021; 48(2): 168. CrossRef
Subclinical sacroiliitis detected by abdominopelvic computed tomography in Korean patients with Crohn’s disease
You-Jung Ha, Hyo Jin Kim, Eugene Lee, Ji Hye Park, Young Soo Park, Yun Jong Lee, Yusuhn Kang, Hyuk Yoon
The Korean Journal of Internal Medicine.2021; 36(4): 868. CrossRef
Proteomic analysis-based discovery of a novel biomarker that differentiates intestinal Behçet’s disease from Crohn’s disease
Jihye Park, Daeun Jeong, Youn Wook Chung, Seunghan Han, Da Hye Kim, Jongwook Yu, Jae Hee Cheon, Ji-Hwan Ryu
Scientific Reports.2021;[Epub] CrossRef
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management
Gerhard Rogler, Abha Singh, Arthur Kavanaugh, David T. Rubin
Gastroenterology.2021; 161(4): 1118. CrossRef
Pancreatic Associated Manifestations in Pediatric Inflammatory Bowel Diseases
Ugo Cucinotta, Claudio Romano, Valeria Dipasquale
Genes.2021; 12(9): 1372. CrossRef
KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 105. CrossRef
Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef
Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef
A review of ophthalmic manifestations of inflammatory bowel disease and associated treatments
Priya Janardhana, Saad Al-Kadhi
Current Opinion in Ophthalmology.2021; 32(6): 549. CrossRef
Etiopathogenic and Clinical Aspects in Inflammatory Bowel Disease – Literature Review
Petronela Nicoleta Seritean Isac, Diana Popescu, Tudor Marcel Genes, Minerva Codruta Badescu, Ioana Irina Rezus, Nicoleta Dima, Ana Roxana Rusu Ganceanu, Elena Rezus, Ciprian Rezus
Journal of Interdisciplinary Medicine.2021; 6(3): 132. CrossRef
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intestinal Research.2021; 19(4): 365. CrossRef
Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
Intestinal Research.2021; 19(4): 478. CrossRef
Ficus pandurata Hance Inhibits Ulcerative Colitis and Colitis‐Associated Secondary Liver Damage of Mice by Enhancing Antioxidation Activity
Weibo Dai, Xinyi Zhan, Weijie Peng, Xin Liu, Weiwen Peng, Quanxi Mei, Xianjing Hu, Kai Wang
Oxidative Medicine and Cellular Longevity.2021;[Epub] CrossRef
Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders
Stefano Mazza, Sara Soro, Maria Chiara Verga, Biagio Elvo, Francesca Ferretti, Fabrizio Cereatti, Andrea Drago, Roberto Grassia
World Journal of Hepatology.2021; 13(12): 1828. CrossRef
Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease
Istvan Fedor, Eva Zold, Zsolt Barta
Journal of Clinical Medicine.2021; 10(24): 5984. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases

Intest Res. 2020;18(3):249-264. Published online April 18, 2020

DOI: https://doi.org/10.5217/ir.2019.00128

XML Download

Figure

Related articles

Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases

Fig. 1. Mechanisms of extraintestinal manifestations (EIMs). (a) Activation and expansion of effector memory T cells can lead to induction of mucosal vascular addressin cell adhesion molecule 1 and C-C motif chemokine ligand 25 (CCL25) expression in the liver. (b) Intercellular adhesion molecule-1, vascular adhesion protein-1, and vascular cell adhesion molecule 1 are associated with T cell trafficking. (c) Microbial antigens and materials translocate to extraintestinal sites and drive EIMs. (d) Circulating antibodies can provoke an autoimmune response and peptide(s) expressing common epitopes shared by colon and extra-colonic organs. (e) Neutrophil priming and alteration of circulating monocytes and macrophages can induce intestinal inflammation and are associated with innate immune responses. (f) Gut dysbiosis drives non-intestinal inflammation and increases mucosal permeability and lipopolysaccharides.

Fig. 1.

Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases

System	Extraintestinal manifestations (prevalence)			Complications of IBD
System	Directly related to bowel disease activity	Not related to bowel disease activity	Unclear relationship to bowel disease activity	IBD or its treatment
Joints/bone	Peripheral arthropathy (2%–20%)		-
	Type 1 peripheral arthritis	Type 2 peripheral arthritis		Metabolic bone disease
	Pauciarthritis	Ankylosing spondylitis (3%–20%)		Osteoporosis/osteopenia
		Axial arthritis (3%–25%)
Skin	Erythema nodosum (1%– 15%)	-	Pyoderma gangrenosum (1%–12%)	Drug-induced skin disease (anti-TNF-induced psoriasis, DIL-E)
				Drug hypersensitivity
				Drug-induced skin cancer
Eye	Episcleritis (<1%)	Uveitis (3%–11%)	-	Drug-induced cataracts
Cardiovascular	-	-	Infective endocarditis (0.2%–2.8%)	Drug-induced myocarditis
			Takayasu’s arteritis (<1%)	Drug-induced pericarditis
			Pericarditis (<1%)
Hepato-pancreato-biliary	-	-	Primary sclerosing cholangitis (0.2%–7.5%)	Drug-induced liver injury
			Nonalcoholic fatty liver disease (8%–59%)	Drug-induced pancreatitis
			Autoimmune hepatitis (0.6%–1.6%)	GB stones
			Granulomatous hepatitis (<1%)	Portal vein thrombosis
Coagulopathy	-	-	-	Venous thromboembolism

System	Extraintestinal manifestations	Diagnosis
Musculoskeletal/joint	Spondyloarthritis	Assessment of SpondyloArthritis International Society modified Berlin algorithm
			Without radiographic sacroiliitis
			HLA-B27 testing
			Evaluated for sacroiliitis by MRI
	Ankylosing spondylitis	Modified New York Classification criteria (≥1 radiological and ≥1 clinical)
		Clinical criteria
			Back pain and stiffness (≥3 months), improves with exercise, but is not relieved by rest
			Limitation of motion of the lumbar spine in both the sagittal and frontal planes
			Limitation of chest expansion relative to normal values correlated for age and sex
		Radiological criterion
			Image of sacroiliitis (grade ≥2 bilaterally or grade ≥3 unilaterally)
Skin	Erythema nodosum	Patient history and physical examination
	Erythema nodosum	Skin biopsy
	Pyoderma gangrenosum	Diagnostic criteria (≥ 1 major & ≥ 4 minor)
		Biopsy of ulcer edge demonstrating neutrophilic infiltrate
			Biopsy of ulcer edge
		Minor criteria
			Exclusion of infection
			Pathergy
			Personal history and history of papule, pustule, or vesicle
			Peripheral erythema, undermining border, and tenderness at site of ulceration
			Multiple ulcerations (≥ 1 anterior lower leg)
			Cribriform or “wrinkled paper” scar(s)
			Decrease in ulcer size within 1 month of initiating immunosuppressive medications
	Psoriasis	History and physical examination (Koebner phenomenon)
	Psoriasis	Skin biopsy (punch biopsy)
	Eczema	Diagnostic criteria
			Evidence of pruritic skin, including the report by a parent of a child rubbing or scratching
		In addition to itchy skin, 3 or more of the following are needed to make the diagnosis:
			History of skin, asthma or hay fever
			Dry skin within the past year
			Symptoms beginning in a child (<2 years of age)
			Visible dermatitis involving flexural surfaces
Eye	Episcleritis/scleritis	History and physical examination
	Episcleritis/scleritis	Slit-lamp biomicroscopy (ophthalmologist)
	Uveitis (anterior or posterior)	History and physical examination
	Uveitis (anterior or posterior)	Slit-lamp biomicroscopy (ophthalmologist)
Cardiovascular	Infective endocarditis	Fever±relevant cardiac risk factors or other predisposing conditions
		Modified Duke criteria
		ECG, CT, TTE, TEE, or chest X-ray
	Takayasu's arteritis	Clinical findings
	Takayasu's arteritis	MRA or CT angiography
	Pericarditis	ECG, echocardiography or chest X-ray
Hepato-pancreato-biliary	PSC	MRCP, ERCP, PTC
	NAFLD	History and rule out other disorders
		US, vibration controlled transient elastography
		CT, MRI or MRS
		Liver biopsy
Coagulopathy	Thromboembolism	Compression ultrasonography with Doppler
Coagulopathy	Thromboembolism	CT

System	Extraintestinal manifestations	NSAIDs	Corticosteroids	5-ASA	MTX/AZA	Immunomodulators	Anti-TNFs
Musculoskeletal/joint	Spondyloarthritis	○	-	○	-	-	○
	Ankylosing spondylitis	○	-	△	△	-	○
	Peripheral arthritis	○	○	◎	○	-	○
Skin	Erythema nodosum	○	◎	-	-	-	○
Skin	Pyoderma gangrenosum	-	◎	-	-	○	○
Eye	Episcleritis/scleritis	○	○	-	△	-	△
Eye	Uveitis	-	○	-	△	△	△
Hepatobiliary	PSC		Ursodeoxycholic acid, ERCP and liver transplantation
	Autoimmune hepatitis		Prednisolone alone or in combination with azathioprine
	Granulomatous hepatitis	-	○	-	-	○	○
Coagulopathy	Deep vein thrombosis	Low-molecular-weight heparin, low-dose unfractionated heparin or fondaparinux
	Pulmonary embolism	Vitamin K antagonist (acenocoumarol, warfarin, fluindione)
	Thromboembolism	Non-vitamin K antagonist oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban)

Table 1. Extraintestinal Manifestations and Complications Associated with IBD

DIL-E, drug-induced lupus erythematosus; GB, gallbladder.

Table 2. Diagnosis of Extraintestinal Manifestations

Table 3. Treatments for Extraintestinal Manifestations